Funding from the Anthem-backed series E round will support the commercialisation of Sera's biomarker tests, which predict the chances of preterm births.
Sera Prognostics, a US-based provider of biomarker tests for pregnant women, closed a $100m series E round co-led by health benefits provider Anthem and investment firm Blue Ox Healthcare Partners yesterday. The round included Vivo Capital, aMoon Fund, Parian Global Management and undisclosed additional backers, and it increased the company’s overall funding to $220m. Founded…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.